Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.34 |
| ▸ | STK17B | O94768 | 1/20 | 0.34 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30605929 | 0.85 | MEN1 (0.37) | — | |
| SCHEMBL3884176 | 0.84 | TRPV1 (0.36) | — | |
| SCHEMBL1127585 | 0.82 | MEN1 (0.42) | — | |
| SCHEMBL2254723 | 0.77 | TRPV1 (0.40) | RXFP1P2RX7 | |
| SCHEMBL1873673 | 0.76 | BRAF (0.49) | LCK | |
| SCHEMBL18616818 | 0.76 | TRPV1 (0.35) | — | |
| SCHEMBL24257006 | 0.75 | TSHR (0.45) | — | |
| SCHEMBL23477989 | 0.75 | MAPK8 (0.34) | — | |
| SCHEMBL1127143 | 0.75 | SLC40A1 (0.46) | LCK | |
| SCHEMBL23458147 | 0.75 | MAPK13 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| EP-4196228-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | Albert Einstein College of Medicine (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036176-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-02-17 | — | — | WO | disclosed |
| US-20190263796-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | CELLIPSE (FR) | 2019-08-29 | — | — | US | disclosed |
| WO-2018055097-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | CELLIPSE (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | BRAF, RAF1, NRAS | ATR 3119/4885AAK1 1970/4885RXFP1 1226/4885 |
| US-20190263796-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | LIMK1, LIMK2, LMTK3 | ATR 1167/4885AAK1 231/4885RXFP1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.